fda compounding semaglutide enforcement news november 2025 Important Update: Changes to Compounded Availability Compounded "semaglutide" is not FDA-approved

Medscapes coverage of the FDAs concerns makes this line clear, and providers who cross it do so without the protections that govern standard clinical practice

Maintenance dose in patients with type 2 diabetes mellitus and chronic kidney disease: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week

By week six, my appetite had shifted in a way that felt natural rather than forced

Another factor relates to delayed gastric emptying

Retatrutide represents a major medical breakthrough

Building Habits That Persist Exercise routines established during Retatrutide treatment are far more likely to continue than new habits started after reaching goal weight